EA031559B1 - Дозированные препараты в качестве модуляторов опиоидного рецептора - Google Patents

Дозированные препараты в качестве модуляторов опиоидного рецептора Download PDF

Info

Publication number
EA031559B1
EA031559B1 EA201591768A EA201591768A EA031559B1 EA 031559 B1 EA031559 B1 EA 031559B1 EA 201591768 A EA201591768 A EA 201591768A EA 201591768 A EA201591768 A EA 201591768A EA 031559 B1 EA031559 B1 EA 031559B1
Authority
EA
Eurasian Patent Office
Prior art keywords
amino
propionyl
ethyl
methyl
phenyl
Prior art date
Application number
EA201591768A
Other languages
English (en)
Russian (ru)
Other versions
EA201591768A1 (ru
Inventor
Енс Йозеф Кеулеманс
Тим Костелло
Эген Мария Йозеф Янс
Филип Эрна Х. Хейнс
Original Assignee
Форест Тосара Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA031559(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Форест Тосара Лтд. filed Critical Форест Тосара Лтд.
Publication of EA201591768A1 publication Critical patent/EA201591768A1/ru
Publication of EA031559B1 publication Critical patent/EA031559B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201591768A 2013-03-14 2014-03-10 Дозированные препараты в качестве модуляторов опиоидного рецептора EA031559B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/829,984 US9675587B2 (en) 2013-03-14 2013-03-14 Opioid receptor modulator dosage formulations
PCT/US2014/022666 WO2014159245A1 (en) 2013-03-14 2014-03-10 Opioid receptor modulator dosage formulations

Publications (2)

Publication Number Publication Date
EA201591768A1 EA201591768A1 (ru) 2016-03-31
EA031559B1 true EA031559B1 (ru) 2019-01-31

Family

ID=51528071

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591768A EA031559B1 (ru) 2013-03-14 2014-03-10 Дозированные препараты в качестве модуляторов опиоидного рецептора

Country Status (21)

Country Link
US (9) US9675587B2 (ja)
EP (3) EP3865131A1 (ja)
JP (2) JP6449225B2 (ja)
KR (1) KR102435440B1 (ja)
CN (2) CN110917159A (ja)
AU (1) AU2014241076B2 (ja)
BR (1) BR112015022753A8 (ja)
CA (1) CA2906472A1 (ja)
CY (1) CY1120892T1 (ja)
DK (1) DK2968351T3 (ja)
EA (1) EA031559B1 (ja)
ES (1) ES2693374T3 (ja)
HK (1) HK1218514A1 (ja)
HU (1) HUE042748T2 (ja)
IL (2) IL241561B (ja)
PL (1) PL2968351T3 (ja)
PT (1) PT2968351T (ja)
SI (1) SI2968351T1 (ja)
TR (1) TR201815953T4 (ja)
TW (1) TWI648071B (ja)
WO (1) WO2014159245A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
CN107847448A (zh) * 2015-05-22 2018-03-27 诺华股份有限公司 药物组合物
CN105250232B (zh) * 2015-09-29 2018-08-14 江苏汇智知识产权服务有限公司 一种伊卢多啉肠溶片及其制备方法
WO2018055528A2 (en) * 2016-09-20 2018-03-29 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018069770A1 (en) * 2016-10-14 2018-04-19 Allergan Holdings Unlimited Company Methods of treatment using eluxadoline
US20210106563A1 (en) * 2019-09-10 2021-04-15 Aurobindo Pharma Ltd Pharmaceutical composition comprising eluxadoline, process of preparation and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050203143A1 (en) * 2004-03-15 2005-09-15 Breslin Henry J. Novel compounds as opioid receptor modulators
US20100249045A1 (en) * 2005-11-02 2010-09-30 Theraquest Biosciences, Inc. Multimodal Abuse Resistant and Extended Release Opioid Formulations
US20120282336A1 (en) * 2009-11-13 2012-11-08 Astrazeneca Uk Limited Bilayer tablet formulations

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US553266A (en) 1896-01-21 Car-fender
US3980766A (en) 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US5574159A (en) 1992-02-03 1996-11-12 Delta Pharmaceuticals, Inc. Opioid compounds and methods for making therefor
US5240929A (en) 1992-08-03 1993-08-31 Warner-Lambert Company 2-heterocyclic-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
FR2713639B1 (fr) 1993-12-09 1996-08-30 Irj Nouveaux dérivés de 2-arylalkényl-azacycloalkanes ligands aux récepteurs sigma, leur procédé de préparation et leur application en thérapeutique.
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
WO1996022997A1 (en) 1995-01-27 1996-08-01 Novo Nordisk A/S Compounds with growth hormone releasing properties
DE19531464A1 (de) 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
US6518292B1 (en) 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
DE19924020A1 (de) 1999-05-26 2000-11-30 Basf Ag Verfahren zur Herstellung von Alkindiolen
US6448323B1 (en) 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
AU2001291040A1 (en) 2000-09-20 2002-04-02 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
HU230376B1 (hu) 2000-10-30 2016-03-29 Janssen Pharmaceutica N.V Tripeptidil peptidáz inhibitorok
ES2361148T3 (es) * 2001-05-11 2011-06-14 Endo Pharmaceuticals Inc. Forma de dosificación de opioides de liberación controlada resistente al abuso.
CA2462953C (en) 2001-10-15 2011-01-04 Janssen Pharmaceutica N.V. Substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives and their use as selective non-peptide delta opioid agonists
US7041681B2 (en) 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
JP2005531557A (ja) 2002-05-17 2005-10-20 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 選択的オピエート受容体モジュレーターとして効果的な化合物の使用
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
WO2007043061A1 (en) * 2005-10-11 2007-04-19 Ipca Laboratories Ltd. Anti-malarial combination and methods of formulation
PT2101740E (pt) * 2006-12-04 2013-12-23 Orexo Ab Nova composição farmacêutica não susceptível de abuso que compreende opióides
AU2008275270C1 (en) 2007-07-09 2014-04-17 Allergan Holdings Unlimited Company Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
ES2692437T3 (es) 2007-08-13 2018-12-03 Abuse Deterrent Pharmaceutical Llc Fármacos resistentes al abuso, método de uso y método de preparación
EP2242485A4 (en) 2008-02-15 2013-05-08 Sun Pharma Advanced Res Co Ltd ORAL TABLET WITH CONTROLLED RELEASE
US20090263476A1 (en) * 2008-04-16 2009-10-22 Jobdevairakkam Christopher N Composition of Rapid Disintegrating Direct Compression Buccal Tablet
US20120065221A1 (en) * 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
US20100285164A1 (en) 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
CA2773003A1 (en) 2009-09-15 2011-03-24 Ratiopharm Gmbh Orally disintegrating pharmaceutical dosage form containing aripiprazole
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
US20220016034A1 (en) 2020-07-17 2022-01-20 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050203143A1 (en) * 2004-03-15 2005-09-15 Breslin Henry J. Novel compounds as opioid receptor modulators
US20100249045A1 (en) * 2005-11-02 2010-09-30 Theraquest Biosciences, Inc. Multimodal Abuse Resistant and Extended Release Opioid Formulations
US20120282336A1 (en) * 2009-11-13 2012-11-08 Astrazeneca Uk Limited Bilayer tablet formulations

Also Published As

Publication number Publication date
EA201591768A1 (ru) 2016-03-31
US11484527B2 (en) 2022-11-01
TWI648071B (zh) 2019-01-21
US20140271854A1 (en) 2014-09-18
WO2014159245A1 (en) 2014-10-02
KR20150140681A (ko) 2015-12-16
CY1120892T1 (el) 2019-12-11
JP6666975B2 (ja) 2020-03-18
AU2014241076A1 (en) 2015-10-01
BR112015022753A2 (pt) 2017-07-18
BR112015022753A8 (pt) 2019-11-26
US9675587B2 (en) 2017-06-13
EP2968351A4 (en) 2016-08-24
US20210205269A1 (en) 2021-07-08
KR102435440B1 (ko) 2022-08-22
JP6449225B2 (ja) 2019-01-09
CN110917159A (zh) 2020-03-27
US11311516B2 (en) 2022-04-26
EP3456321A1 (en) 2019-03-20
HUE042748T2 (hu) 2019-07-29
IL268718A (en) 2019-10-31
JP2019014744A (ja) 2019-01-31
CA2906472A1 (en) 2014-10-02
DK2968351T3 (en) 2018-11-26
US20220008394A1 (en) 2022-01-13
EP2968351B1 (en) 2018-08-29
ES2693374T3 (es) 2018-12-11
US11160792B2 (en) 2021-11-02
CN105228629A (zh) 2016-01-06
US20230293493A1 (en) 2023-09-21
US20220096440A1 (en) 2022-03-31
EP3865131A1 (en) 2021-08-18
US11229627B1 (en) 2022-01-25
JP2016516694A (ja) 2016-06-09
TR201815953T4 (tr) 2018-11-21
IL241561B (en) 2019-09-26
US20220040151A1 (en) 2022-02-10
EP2968351A1 (en) 2016-01-20
AU2014241076B2 (en) 2018-07-19
US20210030720A1 (en) 2021-02-04
US11007179B2 (en) 2021-05-18
TW201444590A (zh) 2014-12-01
US11090291B2 (en) 2021-08-17
US20170304268A1 (en) 2017-10-26
US20210205268A1 (en) 2021-07-08
PT2968351T (pt) 2018-11-19
HK1218514A1 (zh) 2017-02-24
SI2968351T1 (sl) 2019-01-31
IL268718B (en) 2021-04-29
US10188632B2 (en) 2019-01-29
PL2968351T3 (pl) 2019-03-29

Similar Documents

Publication Publication Date Title
US11484527B2 (en) Opioid receptor modulator dosage formulations
WO2009100380A1 (en) Use of ranolazine for treating pain
CN102499923A (zh) 一种药物组合物、其制备方法及用途
US20220016034A1 (en) Opioid receptor modulator dosage formulations
JP2011526909A (ja) テルカゲパントカリウムの固形投与製剤
Das et al. Design and development of a dual-drug loaded pulsatile capsule for treatment of hypertension–in vitro and ex vivo studies
KR101701013B1 (ko) 부정조작 방지 즉각 방출 제형
BR102014003686A2 (pt) composição farmacêutica oral estável
BR102013032395A2 (pt) Composição farmacêutica oral estável

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM